Literature DB >> 28898679

Systemic treatment of renal cell cancer: A comprehensive review.

Amparo Sánchez-Gastaldo1, Emmanuelle Kempf2, Aránzazu González Del Alba3, Ignacio Duran4.   

Abstract

Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Immunotherapy; Monoclonal antibody; Renal cell cancer; Targeted therapy; Tyrosine-kinase inhibitor; mTOR inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28898679     DOI： 10.1016/j.ctrv.2017.08.010

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  60 in total

1.  ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3.

Authors:  Yang-Ling Li; Lin-Wen Wu; Ling-Hui Zeng; Zuo-Yan Zhang; Wei Wang; Chong Zhang; Neng-Ming Lin
Journal:  Oncogene       Date:  2020-08-21       Impact factor: 9.867

2.  Kidney cancer: PSMA: a potential therapeutic target in RCC.

Authors:  Michael A Gorin; Steven P Rowe
Journal:  Nat Rev Urol       Date:  2017-10-17       Impact factor: 14.432

Review 3.  Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Authors:  Kazuhiro Yamamoto; Ikuko Yano
Journal:  Med Oncol       Date:  2018-01-04       Impact factor: 3.064

4.  MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer.

Authors:  Rushika M Perera; Chiara Di Malta; Andrea Ballabio
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

Review 5.  Vessel co-option in cancer.

Authors:  Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

6.  Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma.

Authors:  Gaoteng Lin; Yuanyuan Yang; Qingfu Feng; Fangfang Zhan; Chuangxin Sun; Yuanjie Niu; Gang Li
Journal:  Immunogenetics       Date:  2022-02-04       Impact factor: 2.846

7.  miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5.

Authors:  Chao Yuan; Zhenhong Su; Shengjie Liao; Duanzhuo Li; Zhiwen Zhou; Yawen Wang; Mingchun Quan; Lingling Zeng; Cai Lv; Chenyi Shen; Weida Gong; Jianfeng Wu; Xiaogang Chen; Wenbing Hu; Xu Lv; Wenxia Si; Xin Yu
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 5.722

8.  The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

Authors:  Terri Patricia McVeigh; Raghav Sundar; Nikolaos Diamantis; Stan B Kaye; Udai Banerji; Juanita S Lopez; Johann de Bono; Winette T A van der Graaf; Angela J George
Journal:  Eur J Cancer       Date:  2018-03-31       Impact factor: 9.162

Review 9.  Autophagy in Xp11 translocation renal cell carcinoma: from bench to bedside.

Authors:  Huimin Sun; Xing Wei; Changchun Zeng
Journal:  Mol Cell Biochem       Date:  2021-08-03       Impact factor: 3.396

10.  CYP2J2 Is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.

Authors:  Xiong Zou; Zengnan Mo
Journal:  Biomed Res Int       Date:  2021-06-23       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.